AstraZeneca’s Gout Treatment OK, But Post-Marketing Studies Needed
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Arthritis Drugs Advisory Committee recommends approval of lesinurad despite concerns about safety.
You may also be interested in...
AstraZeneca’s Ardea Acquisition: A Rich Deal Spurred By Phase III Gout Candidate
The $1.26 billion buyout comes as the pharma is looking to bolt-on acquisitions to help offset recent late-stage pipeline disappointments and sees Ardea’s lesinurad as a potential improvement in gout therapy, an estimated $2 billion global market.
US FDA Hopes Food, Inspection Office Reorg Bolsters Innovative Clinical Trial Adoption
Ensuring inspectors understand the innovative trial designs in use before an inspection will be important to increasing industry confidence in their use, CDER Director Patrizia Cavazzoni said.
US FDA's CDER Creates Quantitative Medicine Center Of Excellence; Job Includes AI Oversight
The group will coordinate quantitative medicine issues throughout the FDA's Center for Drug Evaluation and Research to help streamline drug development.